| __timestamp | Amneal Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 335989000 | 14400000 |
| Thursday, January 1, 2015 | 367054000 | 33800000 |
| Friday, January 1, 2016 | 420770000 | 35900000 |
| Sunday, January 1, 2017 | 507476000 | 1254000 |
| Monday, January 1, 2018 | 946588000 | 4889000 |
| Tuesday, January 1, 2019 | 1273376000 | 7400000 |
| Wednesday, January 1, 2020 | 1364130000 | 10100000 |
| Friday, January 1, 2021 | 1324696000 | 14300000 |
| Saturday, January 1, 2022 | 1427596000 | 23200000 |
| Sunday, January 1, 2023 | 1573042000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, understanding cost structures is crucial. From 2014 to 2023, Amneal Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. have shown contrasting trajectories in their cost of revenue. Amneal's cost of revenue surged by approximately 368%, peaking at $1.57 billion in 2023. This reflects their aggressive expansion and market penetration strategies. In contrast, Neurocrine's cost of revenue, though significantly lower, increased by nearly 176%, reaching $39.7 million in 2023. This indicates a more controlled growth approach, focusing on niche markets. The data highlights the diverse strategies employed by these companies in navigating the biopharma sector. As investors and stakeholders analyze these trends, the insights offer a window into the operational efficiencies and market strategies of these industry players.
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Zoetis Inc. vs Amneal Pharmaceuticals, Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Walgreens Boots Alliance, Inc. vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Cost of Revenue Comparison: Amneal Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.